Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Regeneron Pharmaceuticals
Genmab
Genmab
Big Ten Cancer Research Consortium
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
Celgene
Celgene
University of Arizona
Ohio State University Comprehensive Cancer Center
Gilead Sciences
City of Hope Medical Center
Incyte Corporation
Incyte Corporation
The First Affiliated Hospital with Nanjing Medical University
Janssen Research & Development, LLC
University of California, Davis